LivaNova's ROE % for the quarter that ended in Mar. 2024 was -13.43%. LivaNova's PB Ratio for the quarter that ended in Mar. 2024 was 2.48.
LivaNova's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -5.42%.
LivaNova ROE % Adjusted to Book Value Historical Data
The historical data trend for LivaNova's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of LivaNova's ROE % Adjusted to Book Value
For the Medical Devices subindustry, LivaNova's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LivaNova's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where LivaNova's ROE % Adjusted to Book Value falls into.
LivaNova ROE % Adjusted to Book Value Calculation
LivaNova's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LivaNova ROE % Adjusted to Book Value Related Terms
Thank you for viewing the detailed overview of LivaNova's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.
U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LIVN has been successfully added to your 